Trial Profile
A Phase II, Open-label Trial, to Investigate Pharmacokinetics, Safety, Tolerability and Antiviral Activity of TMC114/Rtv b.i.d in Treatment-Experienced HIV-1 Infected Children and Adolescents
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Antiretrovirals; Ritonavir; Ritonavir
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms DELPHI
- Sponsors Janssen Research & Development
- 13 Jan 2011 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 24 Nov 2010 Planned end date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
- 24 Sep 2009 Results were published in AIDS.